Phase 4 N=392 Saxenda in Obesity Services (STRIVE Study)
Obesity · Weight Loss · Diabetes Mellitus
Primary: Weight Loss of ≥15% From Baseline (Complete Cases) — 51; 6 Participants — p=<0.001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=130 Optimal Protamine Dosing for Heparin Reversal Following Cardiopulmonary Bypass
Coagulation; Intravascular
Primary: Activated Clotting Time — 116; 113 seconds
Phase 4 N=18 Ravulizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria Currently Treated With High-Dose Eculizumab
Paroxysmal Nocturnal Hemoglobinuria
Primary: Percentage of Participants Who Experienced Free C5-associated BTH — 0 percentage of participants
Phase 4 N=160 Antibiotics Usage in Pediatric Orthopaedic Percutaneous Surgery (APOPS)
Supracondylar Humerus Fracture · Post Operative Wound Infection
Primary: Number of Participants With the Presence of Post-Operative Infection — 2; 2 Participants
Phase 4 N=40 Role of the Melanocortin-4 Receptor in Hypoactive Sexual Desire Disorder
Hypoactive Sexual Desire Disorder
Primary: Changes in Blood Oxygen Level Dependent (BOLD) Signal Change on Functional MRI — 9.98; 7.67 BOLD signal change
Phase 4 N=15 Long-term Monitoring of Growth and Development of Pediatric Patients Previously Treated With Everolimus
Growth and Development
Primary: Number of Participants Who Achieved Tanner Stage V at or Before Age 16 (Females) or 17 (Males) — 4; 6 Participants
Phase 4 N=3 Cystic Fibrosis and Gut Dysmotility: The Effect of Polyethylene Glycol (PEG) on Intestinal Transit
Cystic Fibrosis Gastrointestinal Disease
Primary: Change is Being Assessed: Total Intestinal Transit Time at Baseline and Two Weeks Following Initiation of Therapy — 41; 42 hours
Phase 4 N=31 A Study to Investigate Efficacy and Safety of VTAMA® (Tapinarof) Cream, 1% in Plaque Psoriasis in the Head and Neck Region
Psoriasis
Primary: Percentage of Participants Who Achieve a Target Lesion Physician Global Assessment (PGA) Score in the Head and Neck Region of Clear (0) or Almost Clear (1) With a ≥…
Phase 4 N=60 Self-Assessment Method for Statin Side-effects Or Nocebo
Adverse Effects · Cardiovascular Diseases · Hyperlipidemias
Primary: Mean Symptom Scores Across Statin, Placebo and no Treatment Periods — 16.3; 15.4; 8.0 units on a scale
Phase 4 N=15 SGLT2 Inhibitors in Transthyretin Amyloid Cardiomyopathy
Transthyretin Amyloid Cardiomyopathy
Primary: Number of Participants Who Experienced a Serious Adverse Event (SAE) — 0 Participants
Phase 4 N=314 Effects of Microplegia on Transfusion Rates After Cardiac Surgery
Aortic Valve Disease · Mitral Valve Disease
Primary: Intraoperative and Postoperative Transfusions — 2.43; 2.97; 4.42; 3.50 units of blood per participant — p=0.354
Phase 4 N=42 Trial Comparing Ceftriaxone Plus Azithromycin Versus Ceftriaxone for the Treatment of Gonorrhea
Neisseria Gonorrhoeae
Primary: Macrolide Resistance Determinants — 110.3; 167.53 normalized determinants/million reads — p=0.1026
Phase 4 N=46 Touch and Feel Evaluation of Two Foam Hand Sanitizers
Hand Hygiene
Primary: Primary Objective Foam Sanitizer User Touch and Feel Experience — 53.21; 39.62; 61.21; 49.73 score on a scale
Phase 4 N=63 A Multicenter Study to Assess Response to Influenza Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab
Relapsing Multiple Sclerosis
Primary: Percentage of Participants Achieving Seroprotection at Week 4 (Observed Case) — 100.00; 100.00; 100.00; 100.00 percentage of participants
Phase 4 N=25 A Study to Evaluate Biomarkers to Predict Efficacy of Abatacept in Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: Number of Participants With American College of Rheumatology (ACR) 20 Response at Week 14 — 9 participants